Tag: Statements

Delivered at the 21st WHO Expert Committee on the Selection and Use of Essential Medicines
G-FINDER Report 2016: The biopharmaceutical industry confirms its status as a significant funder of neglected disease R&D
IFPMA statement on climate change and health
Extension of TRIPS implementation deadline for LDCs
Adoption of the sustainable development goals (SDGs)
WHA 68, Item 11.2 Framework of engagement with non-State actors
WHA 68, Item 15.1 Antimicrobial resistance
LDCs request for extension of TRIPS implementation
WHO Executive Board 136 - Item 9.4, 2014 Ebola virus disease outbreak
WHO EB 136, Item 9.3, Global Vaccine Action Plan
Dr Stefan Oschmann, inaugural speech – transcript
Dr John C. Lechleiter, farewell remarks: chairman, president, and chief executive officer Eli Lilly
United Nations NCD review – Roundtable 2
WHA 67, Item 16.5, Combating antimicrobial resistance, including antibiotic resistance
WHA 67 agenda item 15.6 Regulatory system strengthening (resolution EB134.R19)
Check against delivery – Item 13.3 Prevention and control of non communicable diseases
WHA 67 agenda item 11.3, Framework of engagement with non-State actors
MhGAP forum, Geneva, October 7, 2013
EB 133, Item 6.2, Psoriasis
Agenda item 5, "WHO Reform"
WHA 66 agenda item 13.2 on draft action plan for the prevention and control
WHA 66, Item 16.2, Neglected tropical diseases
WHA 66, Item 17.2, Follow-up of the report of the Consultative Expert Working Group
WHA 66 agenda item 17.1 on Substandard / spurious / falsely-labelled / falsified / counterfeit medical products
WHA 66, Item 13.3, Mental health
UNODC Commission on crime prevention and criminal justice, 22nd session
WHO Executive Board, 132nd session IFPMA statement under agenda item 9.2
WHO Executive Board 132nd session IFPMA statement under agenda item 10.2
WHO Executive Board, 132nd session IFPMA statement under agenda item 5
Open-ended meeting of member States (CEWG)
1 2

Other Tags

Access Access to antiretrovirals Access to Medicines Access to vaccines Africa AMR AMR Industry Alliance Anti-Counterfeit Antibiotics antimicrobial resistance antivirals Biosimilars Biotherapeutic Medicines Biotherapeutics Cancer Clinical Trials Code of Practice collaboration Counterfeit Medicines Counterfeits COVID-19 COVID-19 vaccines Dementia Developing World Diabetes Economic footprint Epidemics Ethics Event Highlights Fake Medicines Fakes Falsified Medicines Fight the Fakes Flu Global Health global health security harmonization Health Health Partnerships HIV/AIDS IFPMA IFPMA Assembly IFPMA Statement Immunization Incremental Innovation Influenza Infographic Infographics Innovation Innovation ecosystem Intellectual Property IP Malaria MDGs Medicines Mental and Neurological Disorders NCDs Neglected Tropical Diseases News Releases Non-Communicable Diseases Novel Coronavirus (COVID-19) NTDs pandemic Pandemic Influenza Pandemic preparedness pandemics partnership Partnerships Pharma Pharmacovigilance Position Paper Prevention Publications Public Health Quality R&D Regulatory regulatory systems Related Links Research Safety SDGs Seasonal Influenza Statements Supply chain Sustainable Development Goals Sustainable Innovation trade Treatments Tuberculosis UHC Universal Health Coverage Vaccine Vaccines Value of Innovation Videos WHA WHO WIPO Women’s Cancers